- Home
- IGR vs GHRS Comparison
IGR vs GHRS Comparison
Compare IGR & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGR
- GHRS
- Stock Information
- Founded
- IGR 2004
- GHRS 2018
- Country
- IGR United States
- GHRS Ireland
- Employees
- IGR N/A
- GHRS N/A
- Industry
- IGR Finance Companies
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- IGR Finance
- GHRS Health Care
- Exchange
- IGR Nasdaq
- GHRS Nasdaq
- Market Cap
- IGR 742.1M
- GHRS 868.7M
- IPO Year
- IGR N/A
- GHRS 2021
- Fundamental
- Price
- IGR $5.14
- GHRS $10.76
- Analyst Decision
- IGR
- GHRS Strong Buy
- Analyst Count
- IGR 0
- GHRS 7
- Target Price
- IGR N/A
- GHRS $30.86
- AVG Volume (30 Days)
- IGR 747.7K
- GHRS 228.5K
- Earning Date
- IGR 01-01-0001
- GHRS 05-02-2025
- Dividend Yield
- IGR 13.93%
- GHRS N/A
- EPS Growth
- IGR N/A
- GHRS N/A
- EPS
- IGR N/A
- GHRS N/A
- Revenue
- IGR N/A
- GHRS N/A
- Revenue This Year
- IGR N/A
- GHRS N/A
- Revenue Next Year
- IGR N/A
- GHRS N/A
- P/E Ratio
- IGR N/A
- GHRS N/A
- Revenue Growth
- IGR N/A
- GHRS N/A
- 52 Week Low
- IGR $3.88
- GHRS $6.00
- 52 Week High
- IGR $5.70
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- IGR 43.51
- GHRS 43.83
- Support Level
- IGR $5.10
- GHRS $10.20
- Resistance Level
- IGR $5.28
- GHRS $13.21
- Average True Range (ATR)
- IGR 0.07
- GHRS 0.86
- MACD
- IGR -0.01
- GHRS -0.06
- Stochastic Oscillator
- IGR 19.44
- GHRS 18.58
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is the United States based diversified, closed-end management investment company. Its objective is high current income and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities located mainly in the developed markets of North America, Europe, Australia, and Asia. Its portfolio of investments consists of different sectors such as diversified, retail, industrial, residential, hotels, healthcare, and other sectors.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.